Pharmaceutical giant Wyeth’s has launched an “ambush” at the beginning of a trial after a nine-year long battle against several generic drug makers, alleging infringement of a second patent for its blockbuster Effexor-XR, a judge heard Monday.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au